admp

1-17
split
niente....
weeeeeeeeeeeeeeeeeeeeee
 
in due anni
abbiamo portato questa micro perla al nasdaq
adesso la musica cambia

mani pesanti pronti a comprare.....................:censored:

maybe
 
in due anni
abbiamo portato questa micro perla al nasdaq
adesso la musica cambia

mani pesanti pronti a comprare.....................:censored:

maybe

sei un cecchino
complimenti
per lo studio che dedichi ogni giorno a questo mercato
con ottimi risultati

carta canta
 
big news::::::

conclusa;

Adamis Pharmaceuticals Announces Completion of Acquisition
SAN DIEGO, CA--(Marketwired - Jan 7, 2014) - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that at a closing held on December 27, 2013, it made a final payment of $7 million to fully acquire from 3M Company and 3M Innovative Properties Company certain intellectual property and assets relating to 3M's Taper Dry Powder Inhaler technology under development for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Adamis intends to utilize the assets initially to undertake efforts to develop a dry powder inhaler device for the treatment of asthma and COPD to deliver the same active ingredients as GlaxoSmithKline's Advair Diskus®. The intellectual property includes patents, patent applications and other intellectual property relating to the Taper assets.

As has previously been reported, on August 1, 2013, Adamis made an initial payment to 3M of $3 million and obtained an exclusive worldwide license to the assets and intellectual property in all indications in the dry powder inhalation field through December 31, 2013. The agreement provided that upon a subsequent closing payment by Adamis of an additional $7 million before December 31, 2013, and satisfaction of other customary closing conditions, ownership of the assets and intellectual property would be transferred to Adamis, with Adamis granting back to 3M a license to the intellectual property assets outside of the dry powder inhalation field.

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. Adamis' current specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease, and APC-3000, an HFA inhaled nasal steroid product for the treatment of allergic rhinitis. The company's vaccine product candidates and cancer drug product candidates under research and development include TeloB-VAX, a cell-based therapeutic cancer vaccine and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer.

Adamis Contacts

Mark Flather
Director, Investor Relations & Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951
mflather@adamispharma.com

Mark Gundy
Capital Group Communications, Inc.
(972) 240-1873
mark.gundy@capitalgc.com
 
looks like the stock could start working it's way into the 7's.

sc.jpg
 
altra perla
portata dall'otc
al
nasdaq
$$$$$$$

MAXIM INITIATES COVERAGE ON ADAMIS PHARMACEUTICALS AT BUY, ANNOUNCES $16.00 PTFont size: A | A | A
undefined undefined | S&P Capital IQ
SNPMarketScopeViewsNews2015-12-01 09:30:40.000ADMPADAMIS PHARMACEUTICALS CORPORATIONAcquire MediaMAXIM INITIATES COVERAGE ON ADAMIS PHARMACEUTICALS AT BUY, ANNOUNCES $16.00 PT Maxim initiates coverage on Adamis Pharmaceuticals (NASDAQ: ADMP) with a Buy rating and a $16.00 price target. Acquire Media|US;ADMP|5401|US|76818
 
newzzzzzzzzzzzzzzzzzzzzzzzzzz


9:00 AM ET 12/7/15 | GlobeNewswire
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Company" or "Adamis") today announced the resubmission of the Company's New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for its Epinephrine Pre-filled Syringe ("PFS") product candidate for the emergency treatment of anaphylaxis. The resubmission is intended to address the issues raised by the FDA in the agency's March 2015 Complete Response Letter ("CRL").

Dr. Dennis J. Carlo, President and CEO of Adamis, stated, "We are excited to be back on track for our Epinephrine Pre-filled Syringe NDA. With the recent changes in the competitive landscape, we believe our product will be better received by patients and payors in that we believe there is an obvious need for a low-cost therapeutic alternative like our PFS product."

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. The Company's current specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease, APC-2000 for the treatment of bronchospasms, and APC-3000, an HFA inhaled nasal steroid product for the treatment of allergic rhinitis. The Company's vaccine product candidates and cancer drug product candidates include TeloB-VAX, a cell-based therapeutic cancer vaccine and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer.
 
xchè sale oggi?
 
Indietro